Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

November 29, 2018

Study Completion Date

November 29, 2018

Conditions
Dry Eye Syndromes
Interventions
DEVICE

TrueTear

TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.

DEVICE

TrueTear Sham Control

TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.

Trial Locations (1)

N2L 3G1

Centre for Contact Lens Research School of Optometry & Vision Science, University of Waterloo, Waterloo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY